By Brian L. Wilson : Vivus (NASDAQ: VVUS ) has been seeing relatively modest growth in Qsymia (phentermine ..... drug market, investors have mixed and overall bearish opinion on VVUS since the FDA approval of Qsymia. The stock is trading at roughly
By Spencer Osborne : When the discussion turns to Arena Pharmaceuticals ( ARNA ), there is no shortage of opinion, passion, and banter. This tends to happen with speculative stocks that gain in popularity. While many think it is an "us against them" situation, the savvy investor steps back, watches
First Manhattan, an investor with about a 10% stake in Vivus ( VVUS ), has now taken the step of increasing its slate of ..... Directors, First Manhattan is seeking to gain control of Vivus through a cherry picked Board of Directors. The sparring
(Reuters) - First Manhattan Company (FMC) added some heavyweight muscle on Thursday to its bid to shake up the board of drugmaker Vivus Inc by naming former Carl Icahn top lieutenant Alex Denner and...
May 23 (Reuters) - First Manhattan Company (FMC) added some heavyweight muscle on Thursday to its bid to shake up the board of drugmaker Vivus Inc by naming former Carl Icahn top lieutenant Alex Denner and two others to its slate of proposed nominees.
in a $65 million milestone payment from Eisai ( ESALY.PK ), more than many movies make and 16-times more than Vivus ' ( VVUS ) first quarter's revenue. This may justify red-carpet treatment since evidence suggests Arena will ultimately
By Spencer Osborne : Some equities have a pretty passionate following. Arena Pharmaceuticals ( ARNA ) happens to be a company that carries a very passionate fan base. On its face this could seem like a great thing, but as with anything in life, there are two sides to any story. The same is true ...
Pharmaceuticals' ( ARNA ) Belviq, and to a lesser extent Vivus ' ( VVUS ) Qsymia (due to changes in REMs), will occur at a ..... also discuss how this phenomenon will also be helpful to Vivus and its weight loss drug Qsymia, my primary focus will
not progressing to the desired point, and cash burn at Vivus ( VVUS ) such that it was faced with either added debt, stock dilution through an offering, or finding a partner, Vivus seems to have chosen the former and came to terms on
Vivus ( VVUS -3.3% ) slips today after pricing its $220M private placement of convertible senior unsecured notes due May 1, 2020. The